V

VistaGen Therapeutics Inc
NASDAQ:VTGN

Watchlist Manager
VistaGen Therapeutics Inc
NASDAQ:VTGN
Watchlist
Price: 2.58 USD 1.98% Market Closed
Market Cap: 71.8m USD
Have any thoughts about
VistaGen Therapeutics Inc?
Write Note

VistaGen Therapeutics Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

VistaGen Therapeutics Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
V
VistaGen Therapeutics Inc
NASDAQ:VTGN
Cash from Financing Activities
$93.4m
CAGR 3-Years
-4%
CAGR 5-Years
49%
CAGR 10-Years
45%
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$2.8B
CAGR 3-Years
45%
CAGR 5-Years
25%
CAGR 10-Years
1%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$6.8B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
-3%
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
-$5.3B
CAGR 3-Years
0%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$1.2B
CAGR 3-Years
1%
CAGR 5-Years
-55%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$1.5B
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

VistaGen Therapeutics Inc
Glance View

Market Cap
69.8m USD
Industry
Biotechnology

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California and currently employs 31 full-time employees. The company went IPO on 2010-10-18. The firm is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The firm's pipeline includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that is preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that is planning for Phase 2b development as a stand-alone treatment for depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. In addition, the Company has developed a human pluripotent stem cell (hPSC) technology platform, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs).

VTGN Intrinsic Value
2.17 USD
Overvaluation 16%
Intrinsic Value
Price
V

See Also

What is VistaGen Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
93.4m USD

Based on the financial report for Sep 30, 2024, VistaGen Therapeutics Inc's Cash from Financing Activities amounts to 93.4m USD.

What is VistaGen Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
45%

Over the last year, the Cash from Financing Activities growth was 172%. The average annual Cash from Financing Activities growth rates for VistaGen Therapeutics Inc have been -4% over the past three years , 49% over the past five years , and 45% over the past ten years .

Back to Top